Eton Pharmaceuticals Gestione
Gestione criteri di controllo 4/4
Eton Pharmaceuticals Il CEO è Sean Brynjelsen, nominato in Jun2017, e ha un mandato di 7.42 anni. la retribuzione annua totale è $ 1.75M, composta da 33.9% di stipendio e 66.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.16% delle azioni della società, per un valore di $ 10.77M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 7.2 anni.
Informazioni chiave
Sean Brynjelsen
Amministratore delegato
US$1.7m
Compenso totale
| Percentuale dello stipendio del CEO | 33.9% |
| Mandato del CEO | 7.4yrs |
| Proprietà del CEO | 4.2% |
| Durata media del management | 2.6yrs |
| Durata media del Consiglio di amministrazione | 7.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Nov 14
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
Oct 07After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
Sep 10Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | US$913k |
| Dec 31 2023 | US$2m | US$592k | -US$936k |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$234k |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$2m | US$570k | -US$9m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$2m | US$542k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$476k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$2m | US$410k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$493k | US$332k | -US$37m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$654k | US$172k | -US$13m |
Compensazione vs Mercato: La retribuzione totale di Sean ($USD 1.75M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.46M ).
Compensazione vs guadagni: La retribuzione di Sean è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sean Brynjelsen (52 yo)
7.4yrs
Mandato
US$1,747,045
Compensazione
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7.4yrs | US$1.75m | 4.16% $ 10.8m | |
| CFO, Treasurer & Secretary | 2.6yrs | US$785.14k | 0.049% $ 126.3k | |
| Chief Business Officer | 1.7yrs | US$719.08k | 0.081% $ 208.4k | |
| Senior Vice President of Quality & Operations | less than a year | Nessun dato | Nessun dato | |
| Vice President of Sales Operations | no data | Nessun dato | Nessun dato | |
| Executive VP of Commercial Operations | 2.8yrs | Nessun dato | Nessun dato |
2.6yrs
Durata media
52yo
Età media
Gestione esperta: Il team dirigenziale di ETON è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7.4yrs | US$1.75m | 4.16% $ 10.8m | |
| Independent Director | 7.2yrs | US$129.50k | 0.23% $ 598.7k | |
| Independent Director | 7.4yrs | US$126.90k | 0.26% $ 685.6k | |
| Independent Chairman | 7.2yrs | US$155.50k | 0.23% $ 598.7k | |
| Independent Director | 3.7yrs | US$119.10k | Nessun dato |
7.2yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ETON sono considerati esperti (durata media dell'incarico 7.2 anni).